GlassScriptPhysician profile
John E Hale
NPI 1417954009
$1,932.24
in general payments reported to CMS, 2019-2025
23 companies · $95.17 in 2025
The $95.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $335 · 2021: $58.17 · 2022: $31.54 · 2023: $121 · 2024: $255 · 2025: $95.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.21 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $281.08 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $252.46 | 2019-2024 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $167.07 | 2019-2025 | Arexvy, Bexsero, Shingrix |
| Astellas Pharma US INC | $119.50 | 2019-2024 | Veozah |
| Lilly USA, LLC | $107.57 | 2019-2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $103.83 | 2019-2020 | |
| Abbvie INC. | $99.70 | 2021-2025 | |
| Pfizer INC. | $80.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.27 | 2019-2024 | Jardiance |
| Sanofi Pasteur INC. | $55.90 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $41.82 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $34.71 | 2023-2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $32.50 | 2019-2020 | |
| Shire North American Group INC | $30.35 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.37 | 2019-2020 | |
| Abbott Laboratories | $19.94 | 2024 | Proclaim |
| Dynavax Technologies Corporation | $16.99 | 2023 | Heplisav-B |
| Genentech USA, INC. | $13.80 | 2019 | |
| Allergan, INC. | $13.12 | 2019 | |
| Amarin Pharma, INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.